March 2019: Our recent computational method for identifying genetic variants that alter RBP-RNA interactions, ASPRIN (Allele-Specific Protein-RNA Interaction), was featured in CHOP’s blog Cornerstone.
September 2018: The NCI Cancer Moonshot Immuno-Oncology Translation Network (IOTN) funded our U01 grant proposal to develop computational tools for identifying cancer immunotherapy targets. This exciting immunotherapeutics discovery program will champion strong collaborative efforts to accelerate cancer research
September 2018: Our lab has moved to Children’s Hospital of Philadelphia and University of Pennsylvania to establish the Center for Computational and Genomic Medicine (CCGM)! The CCGM is dedicated to harnessing big data and genomic technologies in discovering new treatment approaches for children’s health. We are thrilled to join the Philadelphia community and commit ourselves to the CCGM’s bright future.
March 2018: The National Cancer Institute funded our R01 grant proposal to study alternative isoform variation in prostate cancer. We endeavor to discover drugs and biological therapies directed at changes in proteins induced by common cancer-causing genes. The results of our work could lead to new treatments for the nearly half of all cancers that rely on this set of genes.
May 2017: Our R01 grant to study the variation and regulation of alternative splicing in mammalian transcriptomes is renewed by the NIH for four more years.
February 2017: Dr. Xing joins the Scientific Advisory Committee of the Center for Dynamic RNA Epitranscriptomes at the University of Chicago. This is a Center for Excellence in Genomic Sciences (CEGS) funded by the National Human Genome Research Institute, with the main focus being to develop single base, quantitative, and sensitive sequencing methods for RNA modifications.